

# A Single Measurement of Serum Phylloquinone Is an Adequate Indicator of Long-Term Phylloquinone Exposure in Healthy Older Adults<sup>1–3</sup>

Nancy Presse,<sup>4,5</sup> Pierrette Gaudreau,<sup>6,7</sup> Carol E. Greenwood,<sup>8,9</sup> Marie-Jeanne Kergoat,<sup>4,6</sup> Jose A. Morais,<sup>10,11</sup> H el ene Payette,<sup>12,13</sup> Bryna Shatenstein,<sup>4,5</sup> and Guylaine Ferland<sup>4,5\*</sup>

<sup>4</sup>Centre de recherche, Institut Universitaire de G eriatrie de Montr el, Montr el, QC, Canada; <sup>5</sup>D epartement de Nutrition, and <sup>6</sup>D epartement de M edecine, Facult e de M edecine, Universit e de Montr el, Montr el, QC, Canada; <sup>7</sup>Laboratoire de neuroendocrinologie du vieillissement, Centre de Recherche du Centre hospitalier de l'Universit e de Montr el, Montr el, QC, Canada; <sup>8</sup>Department of Nutritional Sciences, University of Toronto, Toronto, ON, Canada; <sup>9</sup>Kunin-Lunenfeld Applied Research Unit, Baycrest, Toronto, ON, Canada; <sup>10</sup>McGill Nutrition and Food Science Centre and Department of Medicine, Division of Geriatrics, McGill University Health Centre, Montr el, QC Canada; <sup>11</sup>School of Dietetics and Human Nutrition, McGill University, Montr el, QC, Canada; <sup>12</sup>Centre de recherche sur le vieillissement, Institut universitaire de g eriatrie de Sherbrooke, Sherbrooke, QC, Canada; and <sup>13</sup>D epartement des sciences de la sant e communautaire, Facult e de m edecine et des sciences de la sant e, Universit e de Sherbrooke, Sherbrooke, QC, Canada

## Abstract

Assessment of long-term phylloquinone exposure is challenging in studies investigating vitamin K in health. Data are equivocal as to whether a single measurement of circulating phylloquinone would be adequate. The primary purpose of the present study was to validate the use of a single measurement of serum phylloquinone as a surrogate for long-term phylloquinone exposure in healthy older adults. Using data from the Qu ebec Longitudinal Study on Nutrition and Successful Aging, the objectives were to: 1) determine the reproducibility of circulating phylloquinone over 2 y ( $n = 234$ ); 2) calculate how a single measurement would rank or classify individuals and attenuate the regression coefficient between circulating phylloquinone and a health outcome; and 3) investigate the association of a single measurement of serum phylloquinone with long-term phylloquinone intakes assessed over the year prior to the blood draw ( $n = 228$ ). The variance analysis based on 2 blood samples showed a fair to good reproducibility for serum phylloquinone (intra-class correlation = 0.49). The correlation coefficient between the ranking of individuals based on a single measurement of circulating phylloquinone and the "true" ranking would be 0.70. The multiple regression analysis showed that long-term phylloquinone intake was the strongest predictor of serum phylloquinone ( $t = 4.94$ ;  $P < 0.001$ ). The partial correlation coefficient ( $r = 0.32$ ) was comparable with those reported in studies where blood sampling and diet recording were juxtaposed and/or multiple blood samples were used. The present study provides evidence that the use of a single measurement of circulating phylloquinone is adequate for assessing long-term phylloquinone exposure in healthy older adults. *J. Nutr.* 142: 1910–1916, 2012.

## Introduction

There is a growing interest in the role of vitamin K in health, especially in aging populations. Given that phylloquinone is the

primary K vitamin in diet and blood (1), phylloquinone intake and/or serum/plasma concentration have typically been used as indicators of vitamin K status (2–11). However, dietary phylloquinone intake is particularly challenging to assess, because intakes are characterized by a high day-to-day variability that requires  $\geq 5$  d of measurement (12,13). Some FFQ have been used (2–4,6,7,10), but because they were designed to characterize overall diet they can lack accuracy when assessing a nutrient found in a limited number of foods such as phylloquinone (14). Dietary assessment is also complicated by the fact that phylloquinone bioavailability varies between food sources. Notably, phylloquinone from oil-based foods (vegetable oils, margarines, dressings) has been shown to be better absorbed than from vegetables (15,16).

In contrast, serum/plasma phylloquinone concentration is reliably determined by HPLC and accounts for differences in

<sup>1</sup> The NuAge Study was supported by research grant MOP-62842 from the Canadian Institutes of Health Research (CIHR) and by the Quebec Network for Research on Aging funded by the Fonds de Recherche du Qu ebec- Sant e (FRQS; formerly Fonds de la Recherche en Sant e du Qu ebec). Access to NuAge databases and measurement of serum phylloquinone were made possible through the NutCog study funded by the research grant MOP-82825 from the CIHR. Nancy Presse was supported by doctoral scholarships from the FRQS and from the CIHR.

<sup>2</sup> Author disclosures: N. Presse, P. Gaudreau, C. E. Greenwood, M.-J. Kergoat, J. Morais, H. Payette, B. Shatenstein, and G. Ferland, no conflicts of interest.

<sup>3</sup> Supplemental Figure 1 and Table 1 are available from the "Online Supporting Material" link in the online posting of the article and from the same link in the online table of contents at <http://jn.nutrition.org>.

\* To whom correspondence should be addressed. E-mail: [guytaine.ferland@umontreal.ca](mailto:guytaine.ferland@umontreal.ca).

phylloquinone bioavailability. However, most epidemiological studies assessing circulating phylloquinone have used one blood sample per individual, whereas the data are equivocal as to whether a single measurement is a valid indicator of long-term phylloquinone exposure. On one hand, metabolic studies have shown circulating phylloquinone to be sensitive to short-term fluctuations in intakes (17–19), and one report found the within-person variance of plasma phylloquinone to be much higher than that between-person (20). On the other hand, 2 studies reported lower within-individual than between-individual variability (21,22) and 2 others found single-sampled plasma phylloquinone to be primarily determined by long-term phylloquinone intake (23,24). Although none of these studies were specifically designed to evaluate the validity of using one measurement of circulating phylloquinone, these conflicting findings would tend to suggest the need for multiple measurements as a precaution. However, such a strategy is invasive and can prove costly in large study samples. It is also an important limitation when using data from existing epidemiological studies where multiple blood samples may not be available.

The primary purpose of the present study was thus to evaluate the reliability of a single measurement of serum phylloquinone concentration as a surrogate for long-term phylloquinone exposure. Because vitamin K has been linked to many age-related outcomes such as bone health and vascular calcification (1), the study was conducted using samples of healthy older adults from the Québec Longitudinal Study on Nutrition and Successful Aging (NuAge)<sup>14</sup> cohort. Specifically, the objectives were to: 1) determine the reproducibility of the serum phylloquinone concentration over 2 y; 2) calculate the degree of accuracy to which a single measurement can rank or classify individuals and estimate the regression coefficient between circulating phylloquinone and a health outcome; and 3) investigate the association of a single measurement of serum phylloquinone with a validated measure of long-term phylloquinone exposure.

## Participants and Methods

**Data source.** The NuAge Study is a prospective cohort study of nutritional factors of successful aging. The methodology has been detailed elsewhere (25). Briefly, 1793 community-dwelling men and women aged 67–84 y were recruited in 2003–2005 from the Québec Medicare Database. At recruitment, participants were in good general health and free of disabilities in activities of daily living and of cognitive impairment (Modified Mini-Mental State Examination score >79). Follow-up interviews were performed annually up to 3 y after recruitment. The present study was conducted using an embedded subsample of 257 healthy adults taking part in a study on nutritional factors in cognitive aging (see Supplemental Fig. 1 for a detailed flowchart). Objectives 1 and 2 were addressed using a variance component analysis including 234 participants for whom phylloquinone concentration was measured in serum samples at the 1- and 3-y NuAge follow-ups. The third objective was addressed using a multiple regression analysis including 228 participants having a serum phylloquinone concentration measured at the 1-y NuAge follow-up and six 24-h dietary recalls (24HR) collected in the year preceding the blood draw. All participants provided informed consent approved by the Ethics committees of both recruitment sites (Instituts universitaires de gériatrie de Montréal and Sherbrooke, QC Canada).

**Serum phylloquinone concentration.** Procedures of blood sampling, processing, and storing at –80°C have been described elsewhere (25). The phylloquinone concentration was measured on 12-h fasting sera

(480 µL) using a well-established HPLC method (26,27). The intra-assay CV were 9.2 and 6.0% for phylloquinone concentrations of 0.2 and 0.8 nmol/L, respectively. The detection limit was 0.03 nmol/L and none of the serum samples were below this limit. Blood samples used in the present study were collected between May 2005 and May 2008. In Canada, over-the-counter supplements containing vitamin K were not available during that period and none of the participants reported taking vitamin K as a prescribed drug. Thus, circulating phylloquinone was from dietary sources only.

**Dietary assessment.** Prior analyses have shown that 6 d of diet recording is the minimum required to properly assess usual phylloquinone intake in older adults (13). Consequently, assessment of long-term phylloquinone intake was based on the 2 sets of 3 nonconsecutive 24HR that were collected 6 mo apart in the year following recruitment into the NuAge. Dietary interview procedures, 24HR processing, and computation of phylloquinone intake were previously detailed (13). Briefly, the multiple-pass method (28) was used by interviewers to limit memory bias and underestimation. Also, every effort was made to assign phylloquinone values to food items with missing data to lessen measurement errors. Energy (MJ), fat (expressed as percent energy), and total phylloquinone intakes were determined for each 24HR. To consider the varying phylloquinone bioavailability among different food sources, phylloquinone intake was also computed according to whether phylloquinone was in a plant food matrix or in an oil phase. Food items were thus divided into 3 food categories: “vegetables and fruits,” “fats, oils, and dressings,” and “mixed dishes and other food items” (e.g., meat products, dairy, food items based on recipes).

**Other determinants of circulating phylloquinone.** Phylloquinone in the bloodstream is mainly carried by TG-rich lipoproteins and, to a lesser extent, by the LDL and HDL fractions, making the blood lipid profile an important determinant of serum/plasma phylloquinone concentration (23,24,29–32). The overnight fasting concentrations of serum TG, total cholesterol, and HDL cholesterol (HDL-C) were determined at the Centre Hospitalier de l’Université de Montréal clinical biochemistry laboratory on a Roche/Hitachi Cobas c311 System analyzer using the TRIGL, CHOL2, and HDLC3 kits, respectively (Roche Diagnostic). The LDL cholesterol (LDL-C) concentration was estimated using the Friedewald equation (33). Other potential determinants included sex, age, race (Caucasian vs. others), BMI, smoking status (never vs. current/former smoker), alcohol consumption, and season of each individual blood draw (May to October vs. November to April). The mean daily consumption of wine, beer, and spirits (a standard drink providing 13.6 g of alcohol) during 12 mo was determined by a validated, semiquantitative, FFQ completed at NuAge baseline (34).

**Statistical analyses.** Participants’ characteristics, serum phylloquinone concentration, and dietary variables are presented as geometric means (95% CI), arithmetic means ( $\pm$  SD), or percentage as appropriate. Student’s *t* tests and  $\chi^2$  were used to compare the study sample with participants not selected from the NuAge cohort. The distribution of serum phylloquinone concentration was positively skewed. Thus, log-transformed data were used in both analytical approaches. Correlation coefficients between participants’ characteristics and the 1-y follow-up serum phylloquinone concentration were determined by regression analysis.

The variance component analysis was based on multilevel modeling using iterative generalized least squares provided by MLwiN 2.20 software (35). Reproducibility of the serum phylloquinone concentration during the 2-y period was assessed by the intra-class correlation (ICC). An ICC <0.40 refers to poor reproducibility of the biomarker,  $\geq 0.40$  to <0.75 is fair to good reproducibility, and  $\geq 0.75$  refers to excellent reproducibility (36). The *r* between the ranking of individuals based on a single measurement of serum phylloquinone and the “true” ranking was calculated using the following equation (13,37):

$$r = \left[ 1 + \frac{\sigma_e^2}{n\sigma_\mu^2} \right]^{-1/2},$$

where *n* is the number of independent blood samples and  $\sigma_e^2/\sigma_\mu^2$  is the within-to-between variance ratio as determined by the variance

<sup>14</sup> Abbreviations used: 24HR, 24-h dietary recall; HDL-C, HDL cholesterol; ICC, intra-class correlation; LDL-C, LDL cholesterol; NuAge, Québec Longitudinal Study on Nutrition and Successful Aging.

component model. Finally, the percentage of attenuation ( $a$ ) of the true regression coefficient was estimated as follows (13,37):

$$a = \left\{ 1 - \left[ 1 + \frac{\sigma_{\epsilon}^2}{\sigma_{\mu}^2} \right]^{-1} \right\} \times 100.$$

The multiple regression analysis was conducted using PASW Statistics 18 software (version 18.0.3; SPSS). Mean daily intakes of energy, percent energy from fats, and phyloquinone (log-transformed) were calculated based on the 6 24HR. Two models were used to evaluate the association between long-term phyloquinone intake and serum phyloquinone, independent of other plausible determinants. In model 1, 2 blocks of variables were specified: block 1 entered sex, age, energy intake, and total phyloquinone intake (log-transformed); and block 2 entered stepwise smoking status, alcohol consumption, BMI, season, percent energy from fats, and serum TG (log-transformed), total cholesterol, LDL-C, and HDL-C concentrations. In model 2, block 1 included sex, age, energy intake, and phyloquinone intake provided by “vegetables and fruits,” “fats, oils, and dressings,” and “mixed dishes and other food items,” and block 2 entered stepwise the same variables as in model 1. The adequacy of the 2 final models was evaluated by: 1) examining added variable plots showing adjusted regression lines; 2) comparing these lines with loess regression lines (Epanechnikov kernel function, 50% fit); 3) assessing normality of residuals; and 4) plotting residuals against predicted values. To evaluate the magnitude of effect in model 1, serum phyloquinone concentration-adjusted means (95%CI) were calculated at the 2.5th, 25th, 50th, 75th, and 97.5th percentiles of total phyloquinone intake.  $P < 0.05$  was considered significant.

## Results

The study sample was aged from 68 to 82 y, with fewer men than women, and was almost entirely Caucasian (99%) (Table 1). The BMI and the serum lipid profile were in the acceptable range for older adults (38,39). Usual phyloquinone intake varied from 13.2 to 302.0  $\mu\text{g}/\text{d}$  (median, 70.7  $\mu\text{g}/\text{d}$ ), with  $59 \pm 20\%$  provided by vegetables and fruits and  $13 \pm 10\%$  (mean  $\pm$  SD) by fats, oils, and dressings. The fasting serum phyloquinone concentration varied from 0.2 to 11.0 nmol/L and 0.1 to 23.4 nmol/L at the NuAge 1- and 3-y follow-ups, respectively. Participants included in the analyses were slightly younger and more educated than those who were not, but they did not differ for sex, race, smoking status, alcohol consumption, BMI, and dietary intakes including phyloquinone (Supplemental Table 1).

**Variance component analysis.** Based on log-transformed data, the within-individual and between-individual variances for serum phyloquinone were 0.044 (95% CI: 0.036–0.052) and 0.043 (95% CI: 0.031–0.055), respectively. The ICC was 0.49 ( $\chi^2 = 66.19$ ;  $P < 0.001$ ), indicating a fair to good reproducibility over 2 y for serum phyloquinone. Considering the variance ratio of 1.02, the ranking of individuals based on a single measurement of serum phyloquinone concentration would be moderately correlated with the “true” ranking ( $r = 0.70$ ), i.e., ~53–58% of individuals would be correctly classified into the extreme fractions of fourths and fifths. The degree of attenuation of the “true” linear regression coefficient would be 50%. The degree of RR attenuation could be estimated using the formula provided by Rosner et al.:  $\{\text{RR}_{\text{observed}} = \exp[\text{ICC} \times \ln(\text{RR}_{\text{true}})]\}$  (40). For example, the true RR of 0.75 would attenuate the observed RR to 0.87. Adjustment for serum TG (log-transformed) and total cholesterol significantly reduced the between-individual variances to 0.030 (95% CI: 0.020–0.040) such that the ICC decreased to 0.41.

**Regression analysis.** Regression modeling showed that sex, age, and energy intakes were not significant determinants of

serum phyloquinone, although women tended to present slightly lower concentrations (Table 2). Stepwise entry of block 2 variables revealed that TG, total cholesterol, and alcohol consumption were independent determinants of circulating phyloquinone in both models. The addition of smoking status, BMI, serum LDL-C and HDL-C concentrations, season, and percent energy from fats did not significantly improve the model or change the regression coefficients (data not shown).

Usual dietary phyloquinone intake was the variable most strongly related to circulating phyloquinone (model 1:  $t = 4.94$ ;  $P < 0.001$ ) followed closely by TG. The partial correlation coefficient between serum phyloquinone concentration and phyloquinone intake was 0.32 and the simple correlation coefficient was 0.21 (Table 1), indicating that the regression model included important cofounders of the relationship. The magnitude analysis for model 1 showed that circulating phyloquinone rose with total phyloquinone intake but at a decreasing rate as phyloquinone intake increased (Fig. 1). When phyloquinone intake was modeled according to food sources (model 2), the adjusted  $R^2$  increased, indicating that phyloquinone intake was better specified in model 2 than in model 1. The regression coefficient for phyloquinone intake from “fats, oils, and dressings” was approximately twice that of phyloquinone intake from “vegetables and fruits” and “mixed dishes and other food items.”

## Discussion

To our knowledge, the present study is the first to provide comprehensive evidence that the use of a single measurement of circulating phyloquinone is adequate for assessment of long-term phyloquinone exposure in healthy older adults, as established by 2 analytical approaches. First, we observed a fair to good reproducibility of serum phyloquinone between 2 blood samples collected 2 y apart, indicating a relative consistency over time. Furthermore, we found that phyloquinone intake assessed during a 1-y period was the primary determinant of serum phyloquinone concentration determined on one nonjuxtaposed blood sample. As a practical guide for researchers, we also determined the degree of accuracy of a single measurement of serum phyloquinone concentration to rank or classify individuals according to their “true” circulating phyloquinone. Furthermore, we provide information on how a single measurement of serum phyloquinone concentration would attenuate the regression coefficient between circulating phyloquinone and a health outcome.

**Variance components of serum phyloquinone.** In the present study, intra-individual variability of serum phyloquinone concentration in healthy older adults was similar to the interindividual variability. Examination of the variance components of circulating phyloquinone is currently limited to data from 3 studies that reported inconsistent results (20–22). In a group of 28 hemodialysis patients, Kohlmeier et al. (21) observed a within : between variance ratio of 0.17, which is indicative of high reproducibility during the study period (3 wk) in these patients. A recent study conducted in 14 healthy adults recruited from laboratory staff and sampled weekly for 22 wk reported an intra-:inter-individual CV ratio of 0.88 (22), showing a variance partitioning similar to what we found. Conversely, Booth et al. (20) reported a within : between variance ratio of 5.4 in a group of 34 healthy volunteers recruited for a metabolic study (17 in each age group: 20–40 and 60–80 y), where participants were sampled 3 times during 20 wk. This variance ratio for phyloquinone is surprisingly high compared with ours, those discussed

**TABLE 1** Description of study participants and correlations with the 1-y NuAge follow-up serum phylloquinone concentration<sup>1</sup>

Variable	<i>n</i>	Value	Correlation coefficient <sup>2</sup>	<i>P</i>
Female, %	257	54	0.01	0.93
Age, <i>y</i>	257	73.6 ± 3.9	0.01	0.93
Former and current smoker, %	257	44	0.07	0.29
Alcohol consumption, <i>drinks/d</i>	252	0.71 ± 1.05	0.08	0.20
BMI, <i>kg/m</i> <sup>2</sup>	257	27.6 ± 4.7	−0.01	0.91
Blood sample drawn from May to October, %	257	68	0.07	0.25
Serum lipid profile				
TG, <i>mmol/L</i>	240	1.41 (1.34–1.48)	0.27	<0.001
Total cholesterol, <i>mmol/L</i>	240	5.07 ± 0.97	0.23	<0.001
LDL-C, <i>mmol/L</i>	240	3.01 ± 0.83	0.18	0.006
HDL-C, <i>mmol/L</i>	240	1.36 ± 0.39	−0.06	0.34
Dietary intakes				
Energy intake, <i>MJ/d</i>	248	7.8 ± 1.8	0.03	0.63
Energy intake from fats, %	248	33 ± 4.9	0.01	0.84
Phylloquinone intake, <i>μg/d</i>				
Total (all food items)	248	72.4 (68.2–77.0)	0.21	0.001
Vegetables and fruits	248	49.1 (44.1–54.5)	0.13	0.04
Fats, oils, and dressings	248	8.3 (7.4–9.4)	0.31	<0.001
Mixed dishes and other food items	248	20.9 (19.6–22.4)	−0.01	0.82
Serum phylloquinone concentration, <i>nmol/L</i>				
1-y follow-up	257	0.96 (0.89–1.04)	–	–
3-y follow-up	234	1.04 (0.95–1.14)	0.50	<0.001

<sup>1</sup> Values are percentages, means ± SD, or geometric means (95% CI), *n* = number of participants with available data. HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; NuAge, Québec Longitudinal Study on Nutrition and Successful Aging.

<sup>2</sup> Correlation coefficients were determined by regression analysis with the 1-y follow-up serum phylloquinone concentration (log-transformed) as dependent variable.

earlier, and even those reported for other fat-soluble vitamins (20,22). The fact that the data from the 2 age groups were pooled may explain the discrepancy. Nonetheless, in all 3 studies, generalization is limited by the small sample sizes and the nature of the participants per se, i.e., hemodialysis patients and nonrandomly selected volunteers.

**Determinants of serum phylloquinone.** Two studies previously examined the relationship between usual phylloquinone intake and single-sampled plasma phylloquinone (23,24). Consistent with our results, long-term phylloquinone intake and TG were found to be the primary determinants of circulating phylloquinone. They also found the relationship between dietary

**TABLE 2** Parameter estimates from fitting multiple regression models testing predictors of log-transformed serum phylloquinone concentration in healthy older adults from the NuAge Study (*n* = 228)

Variables	Model 1		Model 2	
	<i>β</i> Coefficients (SE)	<i>P</i>	<i>β</i> Coefficients (SE)	<i>P</i>
Block 1: enter				
Women	−0.062 (0.040)	0.13	−0.073 (0.039)	0.06
Age, <i>y</i>	0.001 (0.004)	0.82	0.001 (0.004)	0.76
Energy intake (MJ/d)	−0.011 (0.011)	0.33	−0.016 (0.011)	0.16
Phylloquinone intake <sup>1</sup> ( <i>μg/d</i> )				
Total (all food items)	0.423 (0.086)	<0.001	–	–
Vegetables and fruits	–	–	0.113 (0.046)	0.01
Fats, oils, and dressings	–	–	0.224 (0.041)	<0.001
Mixed dishes and other food items	–	–	0.095 (0.075)	0.21
Block 2: stepwise <sup>2</sup>				
Serum TG <sup>1</sup> (mmol/L)	0.504 (0.102)	<0.001	0.468 (0.100)	<0.001
Serum total cholesterol (mmol/L)	0.048 (0.018)	0.009	0.055 (0.018)	0.003
Alcohol consumption (drinks/d)	0.047 (0.018)	0.01	0.050 (0.018)	0.005
<i>R</i> <sup>2</sup> (adjusted- <i>R</i> <sup>2</sup> )	0.23 (0.21)		0.28 (0.25)	

<sup>1</sup> Data were log-transformed. HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; NuAge, Québec Longitudinal Study on Nutrition and Successful Aging.

<sup>2</sup> Variables are presented in order of selection. Smoking status, serum LDL-C and HDL-C, percentage of energy from fats, BMI, and season were not selected in the final models.


intake and serum concentration to be a logarithmic function, which possibly mirrors the saturable energy-mediated mechanism responsible for the intestinal absorption of phyloquinone (41).

Neither of these 2 reports provided the partial correlation coefficients between long-term phyloquinone intake and the single-sampled plasma phyloquinone preventing an appreciation of the ranking agreement between these 2 measurement methods. In the present study, the partial correlation coefficient reported is quite high considering that: 1) the relationship is mediated by digestion, absorption, uptake, utilization, metabolism, excretion, and homeostatic mechanisms (42); 2) blood sampling and diet recording were not juxtaposed; and 3) assessment of long-term phyloquinone intake is characterized by measurement errors attenuating the estimated correlation coefficient (13). Of note, the “deattenuated” partial correlation was estimated at ~0.40, considering an attenuation factor of 0.81 (13). Furthermore, a number of studies examining the relationship between short-term intake and plasma/serum concentration of phyloquinone, where blood sampling and diet recording were juxtaposed and/or multiple blood samples were used, reported correlation coefficients comparable with ours ( $r = 0.32\text{--}0.40$  vs.  $0.13\text{--}0.51$ ) (20,43–45).

The present study reported a significant association between specific phyloquinone food sources and circulating concentrations in an observational design (12,45). Notably, we found that the strength of the association between phyloquinone intake from oil-based foods and serum phyloquinone concentration was twice as strong as the association between phyloquinone intake from fruits and vegetables and serum phyloquinone concentration. This finding is consistent with studies that examined phyloquinone bioavailability. Booth et al. (15) reported that phyloquinone bioavailability, measured as the 24-h AUC, was 1.56–1.66 times higher for a phyloquinone-fortified oil diet than for a broccoli diet. Similarly, a recent study showed phyloquinone bioavailability to be >3 times higher when provided in a meal with >80% of phyloquinone in the oil phase than in meals with >80% of phyloquinone in the vegetable matrix (16). Consistent with previous reports (21,43,44), final models also pointed to triglyceridemia as one of the main determinant of circulating phyloquinone. The significant association with total cholesterol likely originated from phyloquinone carried by the LDL-C and HDL-C fractions (30). The positive effect of alcohol consumption was not observed in previous studies (46,47). Because phyloquinone is soluble in ethanol, the presence of a moderate amount of alcohol in the intestinal lumen may improve phyloquinone solubility and bioavailability.

**Implications for research.** The present report provides important information for planning future population-based research. Collecting one serum or plasma sample per individual would be a cost-effective way to assess long-term phyloquinone exposure. Still, increasing the number of measurements to 2/individual would improve the ranking of individuals ( $r = 0.81$ ) and reduce the attenuation of the regression coefficient to 34%. Results from our study also showed that phyloquinone intake from different food sources was not equally associated with circulating phyloquinone. This observation has important implications when interpreting results from studies using phyloquinone intake as an indicator of phyloquinone exposure. In nutritional epidemiology, where the expected effect size is usually small, the use of circulating phyloquinone could lessen the probability of false negative results by being a better estimate of the amount of phyloquinone directly available to tissues.

Although no earlier studies have specifically evaluated the validity of a single measurement of circulating phyloquinone



**FIGURE 1** Fasting serum phyloquinone concentration as a function of long-term phyloquinone intake in 228 healthy older adults from the NuAge Study. Values are back-transformed means (95% CI) calculated for phyloquinone intake at the 2.5th, 25th, 50th, 75th, and 97.5th percentiles and adjusted for sex, age, energy intake, alcohol consumption, serum TG, and total cholesterol concentrations (model 1). NuAge, Québec Longitudinal Study on Nutrition and Successful Aging.

to assess long-term phyloquinone exposure, previous reports have issued concerns about using a single measure, mainly because metabolic studies showed circulating phyloquinone to be sensitive to short-term fluctuations in intakes (17–19). However, these experimental conditions (e.g., 100 µg phyloquinone/d for 5 d followed by 420 µg/d for 5 d) were tested in the controlled environment of a metabolic ward and were not representative of the real-life context on which observational studies are based. In fact, older adults tend to present stable dietary habits that have been established throughout their life and do not drastically change their diet over time (48,49). Thus, from a nutritional epidemiologic point of view, the use of single serum/plasma sample should not be discarded simply on the basis of the above-mentioned metabolic studies. Furthermore, a recent study provided evidence that fasting serum phyloquinone integrates longer term phyloquinone status in addition to more recent intakes (50). Specifically, when 7 healthy adults ingested 70 µg of isotopically labeled phyloquinone in kale, 2 decay phases were observed, namely, one for plasma elimination (half-time = 8.8 h) and one for tissue elimination (half-time = 9 d). As a result, labeled phyloquinone was detected in fasting plasma for the entire study period (4 wk).

**Strengths and limitations of the study.** Our results are based on a powerful design, including 2 analytical approaches that independently validated the use of a single measurement of circulating phyloquinone. Incidentally, serum phyloquinone and usual phyloquinone intake were in accordance with previous studies conducted in similar populations (14,24,29,51). The NuAge Study sample included healthy older adults, mostly Caucasian, and excluded those who were frail or institutionalized, which could limit generalization. In the present study, a non-random convenience sample of the NuAge cohort was used. Nonetheless, the sample remained large and did not differ substantially from those who were excluded. Usual phyloquinone intake was assessed using the recommended 6 nonconsecutive 24HR (13). The multiple-pass method improved consistency across interviewers and decreased the potential memory bias. The regression analysis included the main plausible determinants of circulating phyloquinone. Still, we cannot rule out the possibility of other potential determinants of circulating phyloquinone such as the apoE genotype. However, the association between the apoE

genotype and circulating phyloquinone is controversial, with studies reporting apoEε4 carriers having a lower (21,52), higher (53), or similar (54) phyloquinone concentration than noncarriers. Finally, we cannot extrapolate our findings to the reproducibility of serum phyloquinone concentrations measured >2 y apart.

In conclusion, based on 2 comprehensive analytical approaches, the present study showed that a single measurement of fasting serum phyloquinone concentration is adequate to assess long-term phyloquinone exposure in healthy older adults. Notably, long-term phyloquinone intake was found to be the primary determinant of single-sampled serum phyloquinone concentration. Our findings also highlight phyloquinone food sources as an important modulator of circulating phyloquinone, pointing to serum concentration as an integrated measure of phyloquinone directly available to tissues. A single measurement of circulating phyloquinone could prove practical and cost-effective for ranking individuals and estimating the magnitude of associations in many observational studies involving healthy older adults.

### Acknowledgments

The authors thank Mira Jabbour, Louise Johnson-Down, and Sylvie Roy for their valuable assistance in analysis of the dietary data and Doriane Kwong Hoi Fung for assistance with the serum phyloquinone analysis. N.P. designed the present study, analyzed the data, and wrote the paper; C.E.G., M-J.K., J.A.M., B.S., and G.F. were NutCog co-investigators; M-J.K. and G.F. were NuAge co-investigators; H.P., P.G., J.A.M., and B.S. were NuAge co-principal investigators, conducted the NuAge Study, and provided access to the NuAge databases; and G.F. supervised the present study and had primary responsibility for final content. All authors read and approved the final manuscript.

### Literature Cited

- Suttie JW. Vitamin K in health and disease. New York: CRC Press Taylor and Francis Group; 2009.
- McLean RR, Booth SL, Kiel DP, Broe KE, Gagnon DR, Tucker KL, Cupples LA, Hannan MT. Association of dietary and biochemical measures of vitamin K with quantitative ultrasound of the heel in men and women. *Osteoporos Int*. 2006;17:600–7.
- Erkkilä AT, Booth SL, Hu FB, Jacques PF, Lichtenstein AH. Phyloquinone intake and risk of cardiovascular diseases in men. *Nutr Metab Cardiovasc Dis*. 2007;17:58–62.
- Maas AH, van der Schouw YT, Beijerinck D, Deurenberg JJ, Mali WP, Grobbee DE, van der Graaf Y. Vitamin K intake and calcifications in breast arteries. *Maturitas*. 2007;56:273–9.
- Tsugawa N, Shiraki M, Sahara Y, Kamao M, Ozaki R, Tanaka K, Okano T. Low plasma phyloquinone concentration is associated with high incidence of vertebral fracture in Japanese women. *J Bone Miner Metab*. 2008;26:79–85.
- Macdonald HM, McGuigan FE, Lanham-New SA, Fraser WD, Ralston SH, Reid DM. Vitamin K1 intake is associated with higher bone mineral density and reduced bone resorption in early postmenopausal Scottish women: no evidence of gene-nutrient interaction with apolipoprotein E polymorphisms. *Am J Clin Nutr*. 2008;87:1513–20.
- Shea MK, Booth SL, Massaro JM, Jacques PF, D'Agostino RB Sr, Dawson-Hughes B, Ordovas JM, O'Donnell CJ, Kathiresan S, Keaney JF Jr, et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. *Am J Epidemiol*. 2008;167:313–20.
- Shea MK, Dallal GE, Dawson-Hughes B, Ordovas JM, O'Donnell CJ, Gundberg CM, Peterson JW, Booth SL. Vitamin K, circulating cytokines, and bone mineral density in older men and women. *Am J Clin Nutr*. 2008;88:356–63.
- Pan Y, Jackson RT. Dietary phyloquinone intakes and metabolic syndrome in US young adults. *J Am Coll Nutr*. 2009;28:369–79.
- Nimptsch K, Rohrmann S, Kaaks R, Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). *Am J Clin Nutr*. 2010;91:1348–58.
- Shea MK, Booth SL, Gundberg CM, Peterson JW, Waddell C, Dawson-Hughes B, Saltzman E. Adulthood obesity is positively associated with adipose tissue concentrations of vitamin K and inversely associated with circulating indicators of vitamin K status in men and women. *J Nutr*. 2010;140:1029–34.
- Booth SL, Sokoll LJ, O'Brien ME, Tucker K, Dawson-Hughes B, Sadowski JA. Assessment of dietary phyloquinone intake and vitamin K status in postmenopausal women. *Eur J Clin Nutr*. 1995;49:832–41.
- Presse N, Payette H, Shatenstein B, Greenwood CE, Kergoat MJ, Ferland G. A minimum of six days of diet recording is needed to assess usual vitamin K intake among older adults. *J Nutr*. 2011;141:341–6.
- Presse N, Shatenstein B, Kergoat MJ, Ferland G. Validation of a semi-quantitative food frequency questionnaire measuring dietary vitamin K intake in elderly people. *J Am Diet Assoc*. 2009;109:1251–5.
- Booth SL, Lichtenstein AH, Dallal GE. Phyloquinone absorption from phyloquinone-fortified oil is greater than from a vegetable in younger and older men and women. *J Nutr*. 2002;132:2609–12.
- Jones KS, Bluck LJ, Wang LY, Stephen AM, Prynne CJ, Coward WA. The effect of different meals on the absorption of stable isotope-labelled phyloquinone. *Br J Nutr*. 2009;102:1195–202.
- Ferland G, Sadowski JA, O'Brien ME. Dietary induced subclinical vitamin K deficiency in normal human subjects. *J Clin Invest*. 1993;91:1761–8.
- Sokoll LJ, Booth SL, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA. Changes in serum osteocalcin, plasma phyloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phyloquinone in human subjects. *Am J Clin Nutr*. 1997;65:779–84.
- Booth SL, O'Brien-Morse ME, Dallal GE, Davidson KW, Gundberg CM. Response of vitamin K status to different intakes and sources of phyloquinone-rich foods: comparison of younger and older adults. *Am J Clin Nutr*. 1999;70:368–77.
- Booth SL, Tucker KL, McKeown NM, Davidson KW, Dallal GE, Sadowski JA. Relationships between dietary intakes and fasting plasma concentrations of fat-soluble vitamins in humans. *J Nutr*. 1997;127:587–92.
- Kohlmeier M, Saupe J, Drossel HJ, Shearer MJ. Variation of phyloquinone (vitamin K1) concentrations in hemodialysis patients. *Thromb Haemost*. 1995;74:1252–4.
- Talwar DK, Azharuddin MK, Williamson C, Teoh YP, McMillan DC, St JORD. Biological variation of vitamins in blood of healthy individuals. *Clin Chem*. 2005;51:2145–50.
- Shea MK, Benjamin EJ, Dupuis J, Massaro JM, Jacques PF, D'Agostino RB Sr, Ordovas JM, O'Donnell CJ, Dawson-Hughes B, Vasani RS, et al. Genetic and non-genetic correlates of vitamins K and D. *Eur J Clin Nutr*. 2009;63:458–64.
- McKeown NM, Jacques PF, Gundberg CM, Peterson JW, Tucker KL, Kiel DP, Wilson PW, Booth SL. Dietary and nondietary determinants of vitamin K biochemical measures in men and women. *J Nutr*. 2002;132:1329–34.
- Gaudreau P, Morais JA, Shatenstein B, Gray-Donald K, Khalil A, Dionne I, Ferland G, Fulop T, Jacques D, Kergoat MJ, et al. Nutrition as a determinant of successful aging: description of the Quebec longitudinal study NuAge and results from cross-sectional pilot studies. *Rejuvenation Res*. 2007;10:377–86.
- Davidson KW, Sadowski JA. Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. *Methods Enzymol*. 1997;282:408–21.
- Wang LY, Bates CJ, Yan L, Harrington DJ, Shearer MJ, Prentice A. Determination of phyloquinone (vitamin K1) in plasma and serum by HPLC with fluorescence detection. *Clin Chim Acta*. 2004;347:199–207.
- Moshfegh A, Borud L, Perloff B, LaComb R. Improved method for the 24-hour dietary recall for use in national surveys. *FASEB J*. 1999;13:A603.
- Sadowski JA, Hood SJ, Dallal GE, Garry PJ. Phyloquinone in plasma from elderly and young adults: factors influencing its concentration. *Am J Clin Nutr*. 1989;50:100–8.

30. Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ. Plasma lipoproteins as carriers of phyloquinone (vitamin K1) in humans. *Am J Clin Nutr.* 1998;67:1226–31.
31. Erkkilä AT, Lichtenstein AH, Dolnikowski GG, Grusak MA, Jalbert SM, Aquino KA, Peterson JW, Booth SL. Plasma transport of vitamin K in men using deuterium-labeled collard greens. *Metabolism.* 2004;53:215–21.
32. Azharuddin MK, O'Reilly DS, Gray A, Talwar D. HPLC method for plasma vitamin K1: effect of plasma triglyceride and acute-phase response on circulating concentrations. *Clin Chem.* 2007;53:1706–13.
33. Burtis CA, Ashwood ER, Bruns DE. *Tietz textbook of clinical chemistry and molecular diagnostics.* 5th ed. St. Louis, MO: Elsevier; 2012.
34. Shatenstein B, Nadon S, Godin C, Ferland G. Development and validation of a food frequency questionnaire. *Can J Diet Pract Res.* 2005;66:67–75.
35. Rasbash J, Browne W, Healy M, Cameron B, Charlton C. MLwiN version 2.20. Bristol (UK): Centre for Multilevel Modelling, University of Bristol; 2010.
36. Kotsopoulos J, Tworoger SS, Campos H, Chung FL, Clevenger CV, Franke AA, Mantzoros CS, Ricchiuti V, Willett WC, Hankinson SE, et al. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. *Cancer Epidemiol Biomarkers Prev.* 2010;19:938–46.
37. Willett W. *Nutritional epidemiology.* 2nd ed. NY: Oxford University Press Inc.; 1998.
38. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation.* 2002;106:3143–421.
39. Cook Z, Kirk S, Lawrenson S, Sandford S. Use of BMI in the assessment of undernutrition in older subjects: reflecting on practice. *Proc Nutr Soc.* 2005;64:313–7.
40. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. *Am J Epidemiol.* 1992;136:1400–13.
41. Hollander D, Rim E, Muralidhara KS. Vitamin K1 intestinal absorption in vivo: influence of luminal contents on transport. *Am J Physiol.* 1977;232:E69–74.
42. Margetts BM, Nelson M, Oxford University Press. *Design concepts in nutritional epidemiology.* 2nd ed. Oxford: Oxford University Press; 1997.
43. Bolton-Smith C, Price R, Fenton S, Harrington D, Shearer MJ. The relationship between plasma and dietary phyloquinone (vitamin K1) in Scottish adults. *Proc Nutr Soc.* 1998;57:148A.
44. Thane CW, Bates CJ, Shearer MJ, Unadkat N, Harrington DJ, Paul AA, Prentice A, Bolton-Smith C. Plasma phyloquinone (vitamin K1) concentration and its relationship to intake in a national sample of British elderly people. *Br J Nutr.* 2002;87:615–22.
45. Thane CW, Wang LY, Coward WA. Plasma phyloquinone (vitamin K1) concentration and its relationship to intake in British adults aged 19–64 years. *Br J Nutr.* 2006;96:1116–24.
46. Rock CL, Thornquist MD, Kristal AR, Patterson RE, Cooper DA, Neuhauser ML, Neumark-Sztainer D, Cheskin LJ. Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins: baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study. *J Nutr.* 1999;129:855–64.
47. Mumma-Schendel LL, Suttie JW. Serum phyloquinone concentrations in a normal adult population. *Am J Clin Nutr.* 1986;44:686–9.
48. Jungjohann SM, Luhrmann PM, Bender R, Blettner M, Neuhauser-Berthold M. Eight-year trends in food, energy and macronutrient intake in a sample of elderly German subjects. *Br J Nutr.* 2005;93:361–78.
49. Toffanello ED, Inelmen EM, Minicuci N, Campigotto F, Sergi G, Coin A, Miotto F, Enzi G, Manzato E. Ten-year trends in dietary intake, health status and mortality rates in free-living elderly people. *J Nutr Health Aging.* 2010;14:259–64.
50. Novotny JA, Kurilich AC, Britz SJ, Baer DJ, Clevidence BA. Vitamin K absorption and kinetics in human subjects after consumption of 13C-labelled phyloquinone from kale. *Br J Nutr.* 2010;104:858–62.
51. Thane CW, Paul AA, Bates CJ, Bolton-Smith C, Prentice A, Shearer MJ. Intake and sources of phyloquinone (vitamin K1): variation with socio-demographic and lifestyle factors in a national sample of British elderly people. *Br J Nutr.* 2002;87:605–13.
52. Saupé J, Shearer MJ, Kohlmeier M. Phyloquinone transport and its influence on gamma-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. *Am J Clin Nutr.* 1993;58:204–8.
53. Yan L, Zhou B, Nigdikar S, Wang X, Bennett J, Prentice A. Effect of apolipoprotein E genotype on vitamin K status in healthy older adults from China and the UK. *Br J Nutr.* 2005;94:956–61.
54. Beavan SR, Prentice A, Stirling DM, Dibba B, Yan L, Harrington DJ, Shearer MJ. Ethnic differences in osteocalcin gamma-carboxylation, plasma phyloquinone (vitamin K1) and apolipoprotein E genotype. *Eur J Clin Nutr.* 2005;59:72–81.